Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2013, Article ID 980471, 8 pages
http://dx.doi.org/10.1155/2013/980471
Research Article

Polymorphisms in PPAR Genes (PPARD, PPARG, and PPARGC1A) and the Risk of Chronic Kidney Disease in Japanese: Cross-Sectional Data from the J-MICC Study

1Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
2Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
3Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan
4Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan
5Department of Health Science, Shiga University of Medical Science, Otsu 520-2192, Japan
6Department of Medicine, University of Calgary, Calgary, AB, Canada T2N 1N4
7Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
8Department of International Island and Community Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan
9Division of Epidemiology, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
10Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
11Department of Social Medicine and Cultural Sciences, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
12Department of Preventive Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
13Center for Genomic Medicine, RIKEN, Yokohama 230-0045, Japan

Received 11 June 2013; Revised 28 August 2013; Accepted 9 September 2013

Academic Editor: Constantinos Giaginis

Copyright © 2013 Asahi Hishida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Yamamoto, A. Kanazawa, T. Shimizu et al., “Association between atherosclerosis and newly classified chronic kidney disease stage for Japanese patients with type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 84, no. 1, pp. 39–45, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Nagata, T. Ninomiya, Y. Doi et al., “Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: the Hisayama study,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2557–2564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Iseki, “Chronic kidney disease in Japan from early predictions to current facts,” Nephron, vol. 110, no. 4, pp. c268–c272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Ninomiya and Y. Kiyohara, “Chronic kidney diseases and other diseases: 1. Cardiovascular diseases,” Nihon Naika Gakkai Zasshi, vol. 96, no. 5, pp. 887–893, 2007 (Chinese). View at Google Scholar · View at Scopus
  5. S. Matsuo, Y. Yasuda, E. Imai, and M. Horio, “Current status of estimated glomerular filtration rate (eGFR) equations for Asians and an approach to create a common eGFR equation,” Nephrology, vol. 15, no. supplement 2, pp. 45–48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. T. S. Perlstein, M. Gerhard-Herman, N. K. Hollenberg, G. H. Williams, and A. Thomas, “Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 944–951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Gluba, D. P. Mikhailidis, G. Y. H. Lip, S. Hannam, J. Rysz, and M. Banach, “Metabolic syndrome and renal disease,” International Journal of Cardiology, vol. 164, no. 2, pp. 141–150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. B. Echouffo-Tcheugui and A. P. Kengne, “Risk models to predict chronic kidney disease and its progression: a systematic review,” PLOS Medicine, vol. 9, no. 11, Article ID e1001344, 2012. View at Publisher · View at Google Scholar
  9. R. M. Evans, G. D. Barish, and Y. X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. G. Nikitin, D. A. Chistiakov, L. O. Minushkina, D. A. Zateyshchikov, and V. V. Nosikov, “Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population,” Heart and Vessels, vol. 25, no. 3, pp. 229–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Azhar, “Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease,” Future Cardiology, vol. 6, no. 5, pp. 657–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Grimaldi, “Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptor β,” Current Opinion in Lipidology, vol. 21, no. 3, pp. 186–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Ruan, F. Zheng, and Y. Guan, “PPARs and the kidney in metabolic syndrome,” American Journal of Physiology, vol. 294, no. 5, pp. F1032–F1047, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. Bhatt, P. Nigam, A. Misra et al., “Association of peroxisome proliferator activated receptor-γ gene with non-alcoholic fatty liver disease in Asian Indians residing in North India,” Gene, vol. 512, no. 1, pp. 143–147, 2013. View at Publisher · View at Google Scholar
  16. H. Uemura, M. Hiyoshi, K. Arisawa et al., “Gene variants in PPARD and PPARGC1A are associated with timing of natural menopause in the general Japanese population,” Maturitas, vol. 71, no. 4, pp. 369–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Hamajima and J-MICC Study Group, “The Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) to detect gene-environment interactions for cancer,” Asian Pacific Journal of Cancer Prevention, vol. 8, no. 2, pp. 317–323, 2007. View at Google Scholar · View at Scopus
  18. K. Wakai, N. Hamajima, R. Okada et al., “Profile of participants and genotype distributions of 108 polymorphisms in a cross-sectional study to elucidate associations between genotypes and lifestyle and clinical factors: a project in the Japan Multi-institutional Collaborative Cohort (J-MICC) Study,” Journal of Epidemiology, vol. 21, no. 3, pp. 223–235, 2010. View at Publisher · View at Google Scholar
  19. S. Matsuo, E. Imai, M. Horio et al., “Revised equations for estimated GFR from serum creatinine in Japan,” American Journal of Kidney Diseases, vol. 53, no. 6, pp. 982–992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Ohnishi, T. Tanaka, K. Ozaki, R. Yamada, H. Suzuki, and Y. Nakamura, “A high-throughput SNP typing system for genome-wide association studies,” Journal of Human Genetics, vol. 46, no. 8, pp. 471–477, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Budtz-Jørgensen, N. Keiding, P. Grandjean, and P. Weihe, “Confounder selection in environmental epidemiology: assessment of health effects of prenatal mercury exposure,” Annals of Epidemiology, vol. 17, no. 1, pp. 27–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. R. Weinberg, “Toward a clearer definition of confounding,” American Journal of Epidemiology, vol. 137, no. 1, pp. 1–8, 1993. View at Google Scholar · View at Scopus
  23. T. Ito, E. Inoue, and N. Kamatani, “Association test algorithm between a qualitative phenotype and a haplotype or haplotype set using simultaneous estimation of haplotype frequencies, diplotype configurations and diplotype-based penetrances,” Genetics, vol. 168, no. 4, pp. 2339–2348, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Andrulionyte, P. Peltola, J. L. Chiasson et al., “Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial,” Diabetes, vol. 55, no. 7, pp. 2148–2152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Stefan, C. Thamer, H. Staiger et al., “Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 5, pp. 1827–1833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Tovar-Palacio, N. Torres, A. Diaz-Villaseñor, and A. R. Tovar, “The role of nuclear receptors in the kidney in obesity and metabolic syndrome,” Genes & Nutrition, vol. 7, no. 4, pp. 483–498, 2012. View at Publisher · View at Google Scholar
  27. T. Yoshida, K. Kato, K. Yokoi et al., “Association of candidate gene polymorphisms with chronic kidney disease in Japanese individuals with hypertension,” Hypertension Research, vol. 32, no. 5, pp. 411–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Grarup, A. Albrechtsen, J. Ek et al., “Variation in the peroxisome proliferator-activated receptor δ gene in relation to common metabolic traits in 7,495 middle-aged white people,” Diabetologia, vol. 50, no. 6, pp. 1201–1208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. D. Shin, B. L. Park, L. H. Kim et al., “Genetic polymorphisms in peroxisome proliferator-activated receptor δ associated with obesity,” Diabetes, vol. 53, no. 3, pp. 847–851, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Lu, Y. Wu, Q. Qi et al., “Associations of type 2 diabetes with common variants in PPARD and the modifying effect of vitamin D among middle-aged and elderly chinese,” PLoS ONE, vol. 7, no. 4, Article ID e34895, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Hu, W. Jia, Q. Fang et al., “Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects,” Diabetic Medicine, vol. 23, no. 12, pp. 1307–1312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. HapMap homepage, http://www.hapmap.org.
  33. A. G. Nikitin, D. A. Chistiakov, L. O. Minushkina, D. A. Zateyshchikov, and V. V. Nosikov, “Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population,” Heart and Vessels, vol. 25, no. 3, pp. 229–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Chehaibi, M. Y. Hrira, M. Rouis et al., “Effect of genetic polymorphism +294T/C in peroxisome proliferator-activated receptor delta on the risk of ischemic stroke in a Tunisian population,” Journal of Molecular Neuroscience, vol. 50, no. 2, pp. 360–367, 2013. View at Publisher · View at Google Scholar
  35. J. Skogsberg, K. Kannisto, T. N. Cassel, A. Hamsten, P. Eriksson, and E. Ehrenborg, “Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 4, pp. 637–643, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. T. C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. C. H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Zhang, S. Zhu, J. Chen et al., “Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies,” Diabetes Care, vol. 35, no. 6, pp. 1388–1393, 2012. View at Publisher · View at Google Scholar
  39. S. B. Gayathri, V. Radha, K. S. Vimaleswaran, and V. Mohan, “Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian indian population (CURES-41),” Metabolic Syndrome and Related Disorders, vol. 8, no. 2, pp. 119–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Yang, X. Mo, S. Chen, X. Lu, and D. Gu, “Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 2, pp. 177–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, “KDIGO clinical practice guideline for acute kidney injury,” Kidney International Supplements, vol. 2, pp. 1–138, 2012. View at Publisher · View at Google Scholar
  42. S. Nakagawa, “A farewell to Bonferroni: the problems of low statistical power and publication bias,” Behavioral Ecology, vol. 15, no. 6, pp. 1044–1045, 2004. View at Publisher · View at Google Scholar · View at Scopus